News Room

Huntington's Disease, Investor Announcement

Prana Biotechnology REACH2HD Investor Conference Call

Prana Biotechnology REACH2HD Investor Conference Call

FEBRUARY 2014: Prana Biotechnology (ASX: PBT/NASDAQ:PRAN) will hold an investor conference call and webcast for professional investors on Wednesday 19th February at 9.30am Australian Eastern Daylight Savings Time (Tuesday 18th February US EST 5.30pm; US PST 2.30pm) to discuss the results of its Reach2HD Phase 2 clinical trial investigating PBT2 as a treatment for Huntington disease.

The trial results announcement is expected to be released later today.

Investors can participate in the event either by webcast or conference call.

Webcast Link

To participate in the webcast please register via the link below up to 15 minutes prior to the scheduled call commencement:

Participants in the webcast will have full access to slides and audio but will not be able to ask questions.

Conference call details

To participate in the conference call, please quote conference ID: 58817510.

Australian Participant Dial-In Numbers

Participants can dial either of the numbers below to join the call. They will need to quote the Conference ID provided above.
Toll: +61 2 8038 5221
Toll-free: 1800 123 296
International Participant Dial-In Numbers

Toll-free dial in numbers for each country are listed below. For countries not listed below, the Australian Toll number provided above may be used.

United States
Hong Kong                  
New Zealand              
United Kingdom          

1855 293 1544
1855 5616 766
4001 203 085
800 908 865
1800 3010 6141
0120 985 190
0800 452 782
800 616 2288
0808 234 0757

The presentation will be available at and lodged on the ASX 15 minutes prior to the call.


A recording of the call will be available within 4 hours of the conclusion of the call at for three months from the date of the call.

Due to the expected high number of participants on the call, we recommend you commence registration for the event 15 minutes prior. 
Global Investor Relations Lead                                 Investor Relations (USA)                 
Rebecca Wilson                                                             Josh Drumm
T: +61 3 9866 4722                                                       T: +1 (347) 327-2863
E:                                    E: